Log in

NASDAQ:GMDA - Gamida Cell Stock Price, Forecast & News

$5.10
+0.01 (+0.20 %)
(As of 12/8/2019 03:51 AM ET)
Today's Range
$4.93
Now: $5.10
$5.11
50-Day Range
$4.72
MA: $4.92
$5.34
52-Week Range
$2.93
Now: $5.10
$15.00
Volume12,927 shs
Average Volume25,254 shs
Market Capitalization$123.53 million
P/E RatioN/A
Dividend YieldN/A
Beta1.74
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GMDA
CUSIPN/A
CIKN/A
Phone972-2659-5666

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.02 per share

Profitability

Net Income$-52,930,000.00

Miscellaneous

Employees70
Market Cap$123.53 million
Next Earnings Date2/24/2020 (Estimated)
OptionableNot Optionable

Receive GMDA News and Ratings via Email

Sign-up to receive the latest news and ratings for GMDA and its competitors with MarketBeat's FREE daily newsletter.


Gamida Cell (NASDAQ:GMDA) Frequently Asked Questions

What is Gamida Cell's stock symbol?

Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."

How were Gamida Cell's earnings last quarter?

Gamida Cell Ltd (NASDAQ:GMDA) released its quarterly earnings data on Wednesday, November, 13th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.07. View Gamida Cell's Earnings History.

When is Gamida Cell's next earnings date?

Gamida Cell is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Gamida Cell.

What price target have analysts set for GMDA?

2 Wall Street analysts have issued 1-year target prices for Gamida Cell's shares. Their forecasts range from $16.00 to $18.00. On average, they expect Gamida Cell's share price to reach $17.00 in the next twelve months. This suggests a possible upside of 233.3% from the stock's current price. View Analyst Price Targets for Gamida Cell.

What is the consensus analysts' recommendation for Gamida Cell?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gamida Cell.

Has Gamida Cell been receiving favorable news coverage?

News coverage about GMDA stock has trended somewhat positive recently, according to InfoTrie. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Gamida Cell earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an impact on the company's share price in the next several days. View News Stories for Gamida Cell.

Are investors shorting Gamida Cell?

Gamida Cell saw a decline in short interest during the month of November. As of November 15th, there was short interest totalling 44,800 shares, a decline of 5.1% from the October 31st total of 47,200 shares. Based on an average trading volume of 30,300 shares, the short-interest ratio is currently 1.5 days. Currently, 0.4% of the shares of the stock are sold short. View Gamida Cell's Current Options Chain.

Who are some of Gamida Cell's key competitors?

What other stocks do shareholders of Gamida Cell own?

Who are Gamida Cell's key executives?

Gamida Cell's management team includes the folowing people:
  • Julian Adams, Chief Executive Officer & Director
  • Yael Margolin, President
  • Tzvi Palash, Chief Operating Officer
  • Shai Lankry, Chief Financial & Accounting Officer
  • Tony Peled, Chief Scientific Officer, Vice President-R&D

When did Gamida Cell IPO?

(GMDA) raised $50 million in an initial public offering (IPO) on Friday, October 26th 2018. The company issued 3,600,000 shares at $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

Who are Gamida Cell's major shareholders?

Gamida Cell's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (0.29%) and Phoenix Holdings Ltd. (0.12%).

Which major investors are buying Gamida Cell stock?

GMDA stock was acquired by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd. and Millennium Management LLC.

How do I buy shares of Gamida Cell?

Shares of GMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Gamida Cell's stock price today?

One share of GMDA stock can currently be purchased for approximately $5.10.

How big of a company is Gamida Cell?

Gamida Cell has a market capitalization of $123.53 million. The company earns $-52,930,000.00 in net income (profit) each year or ($10.53) on an earnings per share basis. Gamida Cell employs 70 workers across the globe.View Additional Information About Gamida Cell.

What is Gamida Cell's official website?

The official website for Gamida Cell is http://www.gamida-cell.com/.

How can I contact Gamida Cell?

Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The company can be reached via phone at 972-2659-5666 or via email at [email protected]


MarketBeat Community Rating for Gamida Cell (NASDAQ GMDA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  59 (Vote Outperform)
Underperform Votes:  59 (Vote Underperform)
Total Votes:  118
MarketBeat's community ratings are surveys of what our community members think about Gamida Cell and other stocks. Vote "Outperform" if you believe GMDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GMDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel